MOVIFAST
Oral Solution

Macrogol 3350 & Electrolytes

Composition
MOVIFAST Oral Solution: Each 25 ml concentrated oral solution contains Macrogol 3350 BP 13.1250 gm, Sodium Chloride USP 0.3507 gm, Sodium Bicarbonate USP 0.1785 gm, Potassium Chloride USP 0.0466 gm.

Pharmacology
Macrogol 3350 exerts an osmotic action in the gut, which induces a laxative effect. Macrogol 3350 increases the stool volume, which triggers colon motility via neuromuscular pathways. The physiological consequence is an improved propulsive colonic transportation of the soften stools and a facilitation of the defecation. Electrolytes combined with Macrogol 3350 are exchanged across the intestinal barrier (mucosa) with serum electrolytes and excreted without net gain or loss of sodium, potassium and water. Macrogol 3350 is unchanged along the gut. It is virtually unabsorbed from the gastrointestinal tract.

Indication
For use in adults and children over 12 years of age for effective relief from constipation and treatment of occasional and chronic constipation. Also effective in resolving fecal impaction, defined as refractory constipation with fecal loading of the rectum and colon.

Dosage and Administration
Measure 25 mL of **MOVIFAST Oral Solution** with measuring cup provided, then add this to 100 mL of water. Any unused diluted solution should be discarded within 24 hours.



Adults:
Occasional and chronic constipation: 25 mL of **MOVIFAST Oral Solution** added to 100 mL of water once daily (to make a total volume of 125 mL).This may be increased to 2 - 3 doses of 25 mL daily (each 25 mL dose added to 100 mL of water), if required according to individual response.
Fecal Impaction: 8 doses of 25 mL daily (each 25 mL dose added to 100 mL of water). A course of treatment for Fecal impaction does not normally exceed 3 days.
Children (12-18 years): 25 mL of **MOVIFAST Oral Solution** added to 100 mL of water once daily.

Contraindication
Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, ileus, severe inflammatory conditions of the intestinal tract, such as Crohn's disease and Ulcerative colitis and Toxic megacolon. Hypersensitivity to the active substances.

Precaution
This medicinal product contains 8.125 mmol of sodium in each dose of 25 mL.The sodium content of **MOVIFAST Oral Solution** should be taken into consideration when administering the product to patients on a controlled sodium diet.

Side Effect
In the treatment of Chronic Constipation, Diarrhea or loose stools normally respond to a reduction in dose. Diarrhoea, Abdominal distension, Anorectal discomfort and mild vomiting are more often observed during the treatment for Fecal impaction. Vomiting may be resolved if the dose is reduced or delayed.

Use In Pregnancy & Lactation
Clinically, no effects during pregnancy are anticipated, since systemic exposure to Macrogol 3350 is negligible. **MOVIFAST Oral Solution** can be used during pregnancy.
No effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breast-feeding woman to Macrogol 3350 is negligible. **MOVIFAST Oral Solution** can be used during breast-feeding.

Drug Interaction
There is a possibility that the absorption of other medicinal products could be transiently reduced during use with **MOVIFAST Oral Solution**. There have been isolated reports of decreased efficacy with some concomitantly administered medicinal products, e.g. Anti-epileptics.

Overdose
Extensive fluid loss by diarrhea or vomiting may require correction of electrolyte disturbances.

Storage
Store below 30^{0}C and in a place protected from light. Do not refrigerate. Discard any remaining **MOVIFAST Oral Solution** 30 days after first opening the bottle.

How Supplied
MOVIFAST Oral Solution : Each box contains 100 mL concentrated oral solution in bottle with a measuring cup.

Manufactured by:
ZISKA PHARMA
Ziska Pharmaceuticals Ltd.
Kaliakoir, Gazipur, Bangladesh